Pharmacology

Action Mechanism of Action Reference
HYDROLYTIC ENZYME Hyaluronic acid hydrolytic enzyme

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Pain 3 D010146 ClinicalTrials
Myocardial Infarction 3 D009203 ClinicalTrials
Myocardial Ischemia 3 D017202 ClinicalTrials
Bursitis 3 D002062 ClinicalTrials
Multiple Myeloma 3 D009101 ClinicalTrials
Lymphoma, Follicular 3 D008224 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 3 D002289 ClinicalTrials
Lymphoma 3 D008223 ClinicalTrials
Coronary Disease 3 D003327 ClinicalTrials
Amyloidosis, Familial 3 D028226 ClinicalTrials
Lymphoma, Mantle-Cell 2 D020522 ClinicalTrials
Leukemia, Biphenotypic, Acute 2 D015456 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 2 D016403 ClinicalTrials
Muscle Spasticity 2 D009128 ClinicalTrials
Melanoma 2 D008545 ClinicalTrials
Neoplasms 2 D009369 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-Cell 2 D015451 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Prostatic Neoplasms 2 D011471 ClinicalTrials
Melanoma 2 D008545 ClinicalTrials
Graves Ophthalmopathy 2 D049970 ClinicalTrials
Anemia, Hemolytic 1 D000743 ClinicalTrials
Neuralgia 1 D009437 ClinicalTrials
Diabetes Mellitus, Type 1 1 D003922 ClinicalTrials
Hypersensitivity 1 D006967 ClinicalTrials

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Skin and subcutaneous tissue disorders
23.53
General disorders and administration site conditions
22.35
Eye disorders
18.82
Immune system disorders
12.94
Nervous system disorders
8.24
Injury, poisoning and procedural complications
4.71
Endocrine disorders
2.35
Gastrointestinal disorders
2.35

Cross References

Resources Reference
CAS NUMBER 9001-54-1
ChEMBL CHEMBL1201636
FDA SRS 8KOG53Z5EM